Advanced pain management for cats addresses the challenge of species-specific drug limitations through multimodal approaches and new biologics.
Feline pain management has historically been limited by NSAID intolerance that leaves cats without adequate analgesic options available to dogs. The development of Solensia specifically for cats addresses chronic arthritis pain safely. Multimodal protocols combining buprenorphine, gabapentin, and biologics provide comprehensive pain management for complex feline pain conditions. These advances directly improve welfare for the millions of cats experiencing chronic pain.